Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FK506-binding protein 12 (FKBP12) F36V-containing fusion proteins are synthetic constructs designed for use in cell-based therapies to provide precise pharmacological control over cellular activities. This system utilizes a modified version of the human FKBP12 protein featuring a phenylalanine-to-valine substitution at position 36 (F36V), which creates a unique hydrophobic pocket. This pocket specifically binds to "bumped" synthetic ligands like rimiducid (AP1903) with high affinity, while avoiding interaction with endogenous wild-type FKBP12 or natural ligands like FK506 [1][2]. The most prominent application is the inducible Caspase-9 (iCasp9) safety switch, where the FKBP12(F36V) domain is fused to a truncated human Caspase-9. Upon administration of rimiducid, the drug acts as a chemical inducer of dimerization (CID), cross-linking two fusion proteins and triggering the apoptotic cascade to eliminate the engineered cells [1][3]. Beyond safety switches, these fusion proteins are also employed in inducible activation systems, such as the iMC (inducible MyD88/CD40) platform, to enhance the potency and persistence of chimeric antigen receptor (CAR) T cells in treating various cancers [4]. This technology allows clinicians to mitigate severe toxicities like graft-versus-host disease or cytokine release syndrome by selectively depleting the therapeutic cells. References: [1] Di Stasi A, et al. N Engl J Med. 2011;365(18):1673-1683. [2] Clackson T, et al. Proc Natl Acad Sci U S A. 1998;95(18):10437-10442. [3] Gargett T, Brown MP. Front Pharmacol. 2014;5:235. [4] Foster AE, et al. Mol Ther. 2017;25(5):1076-1085.
Rimiducid acts as a bivalent chemical inducer of dimerization (CID) that binds to two FKBP12(F36V) domains simultaneously, bringing the attached effector proteins into close proximity to initiate downstream biological signaling or apoptosis [1][3].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FK506-binding protein 12 F36V-containing fusion protein (FKBP12(F36V) fusion protein).